NCT04511533 2024-04-05Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating MutationsPfizerPhase 4 Completed101 enrolled 11 charts
NCT01774721 2023-11-14ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.PfizerPhase 3 Completed452 enrolled 35 charts 1 FDA
NCT01000025 2023-08-22PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic CancerCanadian Cancer Trials GroupPhase 3 Completed720 enrolled 14 charts
NCT01918761 2019-12-30Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)Central European Cooperative Oncology GroupPhase 1 Terminated5 enrolled 27 charts
NCT00548093 2019-05-21PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And ErlotinibPfizerPhase 2 Completed66 enrolled 19 charts
NCT01858389 2017-07-18A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung CancerPfizerPhase 2 Completed41 enrolled 16 charts
NCT01121575 2015-10-28A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung CancerPfizerPhase 1 Completed70 enrolled 50 charts
NCT00769067 2015-10-07A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy RegimenPfizerPhase 2 Completed188 enrolled 14 charts